Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 4693-4700, September 1, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martikainen, P.
Right arrow Articles by Isaacs, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martikainen, P.
Right arrow Articles by Isaacs, J. T.

Programmed Death of Nonproliferating Androgen-independent Prostatic Cancer Cells1

Paula Martikainen2, Natasha Kyprianou3, Robert W. Tucker and John T. Isaacs4

The Johns Hopkins Oncology Center [P. M., N. K., R. W. T., J. T. I.], James Buchanan Brady Urological Institute, and the Department of Urology [J. T. I.], Johns Hopkins School of Medicine, Baltimore, Maryland 21205

Androgen ablation induces an energy-dependent process of programmed death in nonproliferating androgen-dependent prostatic cancer cells which involves fragmentation of genomic DNA into nucleosomal oligomers catalyzed by nuclear Ca2+, Mg2+-dependent endonuclease enzymes activated following a sustained elevation in intracellular free Ca2+ (Ca1). In contrast, androgen-independent prostatic cancer cells are not induced to undergo such programmed cell death by androgen ablation. One explanation for the inability of androgen ablation to induce programmed death of androgen-independent prostatic cancer cells is that such ablation does not result in a sustained elevation in Ca1 in these cells. This raises the issue of whether androgen-independent prostatic cancer cells can be induced to undergo programmed death if an elevation in the Ca1 is sufficiently sustained by nonhormonal means.

To test this possibility, androgen-independent, highly metastatic Dunning R-3327 AT-3 rat prostatic cancer cells were chronically exposed in vitro to the calcium ionophore ionomycin to sustain an elevation in their Ca1. These studies demonstrated that an elevation of Ca1 as small as only 3-6-fold above baseline can induce the death of these cells if sustained for > 12 h. Temporal analysis demonstrated that the death of these cells does not require cell proliferation and involves Ca2+-induced fragmentation of genomic DNA into nucleosome-sized pieces as the commitment step in this process. These results demonstrate that even nonproliferating androgen-independent prostatic cancer cells can be induced to undergo programmed cell death if a modest elevation in the Ca1 is sustained for a sufficient time. These observations identify Ca1 as a potential target for therapy for androgen-independent prostatic cancer cells.

1 Supported by NIH Grant CA50601. Partly supported by National Cancer Institute Grant 5-P30-CA06973.

2 P. M. was a Fogarty Fellow supported by Grant FOSTW04050 during these studies. Present address: Department of Pathology, University of Turku, SF-20520, Finland.

3 Present address: Division of Urology, University of Maryland, 22 S. Greene Street, Baltimore, MD 21201.

4 To whom requests for reprints should be addressed, at 422 N. Bond Street, Baltimore, MD 21231.

Received 3/18/91. Accepted 6/25/91.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
F. Van Coppenolle, F. Vanden Abeele, C. Slomianny, M. Flourakis, J. Hesketh, E. Dewailly, and N. Prevarskaya
Ribosome-translocon complex mediates calcium leakage from endoplasmic reticulum stores
J. Cell Sci., August 15, 2004; 117(18): 4135 - 4142.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Cifuentes, J. M. Mataraza, B. A. Yoshida, M. Menon, D. B. Sacks, E. R. Barrack, and G. P.-V. Reddy
Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells
PNAS, January 13, 2004; 101(2): 464 - 469.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. R. Denmeade, C. M. Jakobsen, S. Janssen, S. R. Khan, E. S. Garrett, H. Lilja, S. B. Christensen, and J. T. Isaacs
Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer
J Natl Cancer Inst, July 2, 2003; 95(13): 990 - 1000.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
Y. ZHANG, B. NAN, J. YU, T. SNABBOON, F. ANDRIANI, and M. MARCELLI
From Castration-Induced Apoptosis of Prostatic Epithelium to the Use of Apoptotic Genes in the Treatment of Prostate Cancer
Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 191 - 203.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. C. Ferrari, N. Stone, R. Stock, M. Bednar, I. Esseesse, H. Singh, Y. Baldwin, and J. Mandeli
13-cis Retinoic Acid and Complete Androgen Blockade in Advanced Hormone-Naive Prostate Cancer Patients: Report of a Phase II Randomized Study
J. Clin. Oncol., January 15, 2002; 20(2): 538 - 544.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Barnett, A.-M. Jakobsen, M. Tas, K. Rice, J. Carmichael, and J. C. Murray
Prostate Adenocarcinoma Cells Release the Novel Proinflammatory Polypeptide EMAP-II in Response to Stress
Cancer Res., June 1, 2000; 60(11): 2850 - 2857.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Zhu and Z. Wang
Calreticulin Expression Is Associated with Androgen Regulation of the Sensitivity to Calcium Ionophore-induced Apoptosis in LNCaP Prostate Cancer Cells
Cancer Res., April 1, 1999; 59(8): 1896 - 1902.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Uemura and C. Chang
Antisense TR3 Orphan Receptor Can Increase Prostate Cancer Cell Viability with Etoposide Treatment
Endocrinology, May 1, 1998; 139(5): 2329 - 2334.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. E. Reynolds and A. Eastman
Intracellular Calcium Stores Are Not Required for Bcl-2-mediated Protection from Apoptosis
J. Biol. Chem., November 1, 1996; 271(44): 27739 - 27743.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
D. McConkey and S Orrenius
Signal transduction pathways in apoptosis
Stem Cells, November 1, 1996; 14(6): 619 - 631.
[Abstract]


Home page
NEJMHome page
J. Narula, N. Haider, R. Virmani, T. G. DiSalvo, F. D. Kolodgie, R. J. Hajjar, U. Schmidt, M. J. Semigran, G. W. Dec, and B.-A. Khaw
Apoptosis in Myocytes in End-Stage Heart Failure
N. Engl. J. Med., October 17, 1996; 335(16): 1182 - 1189.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
F Oberhammer, G Fritsch, M Schmied, M Pavelka, D Printz, T Purchio, H Lassmann, and R Schulte-Hermann
Condensation of the chromatin at the membrane of an apoptotic nucleus is not associated with activation of an endonuclease
J. Cell Sci., January 2, 1993; 104(2): 317 - 326.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
Z. Pan, D. Damron, A.-L. Nieminen, M. B. Bhat, and J. Ma
Depletion of Intracellular Ca2+ by Caffeine and Ryanodine Induces Apoptosis of Chinese Hamster Ovary Cells Transfected with Ryanodine Receptor
J. Biol. Chem., June 23, 2000; 275(26): 19978 - 19984.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.